γδ T 细胞可预测唑来膦酸盐治疗的乳腺癌患者的预后。
γδ T cells predict outcome in zoledronate-treated breast cancer patients.
出版信息
Oncologist. 2013;18(8):e22-3. doi: 10.1634/theoncologist.2013-0097.
Abstract
The biological mechanism underlying the antitumor role of zoledronate is unclear. The analysis in this letter illustrates the diagnostic and prognostic potential of a γδ T-cell-based blood test and implies a link between immune responsiveness and positive outcome with zoledronate therapy.
摘要
唑来膦酸抗肿瘤作用的生物学机制尚不清楚。本研究分析说明了基于 γδ T 细胞的血液检测的诊断和预后潜力，并提示免疫反应性与唑来膦酸治疗的良好预后之间存在关联。
相似文献
1
γδ T cells predict outcome in zoledronate-treated breast cancer patients.γδ T 细胞可预测唑来膦酸盐治疗的乳腺癌患者的预后。
Oncologist. 2013;18(8):e22-3. doi: 10.1634/theoncologist.2013-0097.
2
Role of zoledronate in aromatase activity should be considered in future studies.唑来膦酸在芳香化酶活性中的作用应在未来的研究中加以考虑。
Oncologist. 2013;18(8):e25. doi: 10.1634/theoncologist.2013-0208.
3
In reply.回复。
Oncologist. 2013;18(8):e26-7. doi: 10.1634/theoncologist.2013-0235.
4
Adjuvant therapy with zoledronic Acid and menopausal status.唑来膦酸辅助治疗与绝经状态。
Oncologist. 2013;18(8):e24. doi: 10.1634/theoncologist.2013-0109.
5
Zoledronic acid and its accentuating effect on tumor radiosensitivity.唑来膦酸及其对肿瘤放射敏感性的增强作用。
Oncologist. 2013;18(8):e21. doi: 10.1634/theoncologist.2013-0054.
6
S0307. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer.S0307. 双膦酸盐作为原发性乳腺癌辅助治疗的III期试验。
Clin Adv Hematol Oncol. 2005 Nov;3(11):852-4.
7
Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against.乳腺癌中双膦酸盐常规辅助使用的支持与反对观点
Crit Rev Oncol Hematol. 2010 Apr;74 Suppl 1:S11-5. doi: 10.1016/S1040-8428(10)70005-6.
8
Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer.医学肿瘤学：唑来膦酸可预防早期乳腺癌患者的骨质流失。
Nat Rev Clin Oncol. 2009 Apr;6(4):191-2. doi: 10.1038/nrclinonc.2009.24.
9
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).早期乳腺癌蒽环类-紫杉烷类化疗后侵袭性残留疾病患者使用唑来膦酸——III期新辅助试验附加研究（NaTaN）（GBG 36/ABCSG 29）
Eur J Cancer. 2016 Sep;64:12-21. doi: 10.1016/j.ejca.2016.05.015. Epub 2016 Jun 17.
10
Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.唑来膦酸使神经母细胞瘤来源的肿瘤起始细胞对人 γδ T 细胞介导的细胞溶解敏感。
J Immunother. 2012 Oct;35(8):598-606. doi: 10.1097/CJI.0b013e31826a745a.
引用本文的文献
1
Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8 T cells.人γδ T细胞和CD8 T细胞对乳腺癌干细胞样细胞的协同靶向作用。
Immunol Cell Biol. 2017 Aug;95(7):620-629. doi: 10.1038/icb.2017.21. Epub 2017 Mar 30.
2
Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome.黑色素瘤中循环Vγ9Vδ2 T淋巴细胞的分化偏向及其对临床结局的影响
PLoS One. 2016 Feb 25;11(2):e0149570. doi: 10.1371/journal.pone.0149570. eCollection 2016.
3
The best of both worlds - managing the cancer, saving the bone.两全其美——对抗癌症，保护骨骼。
Nat Rev Endocrinol. 2016 Jan;12(1):29-42. doi: 10.1038/nrendo.2015.185. Epub 2015 Oct 27.
4
Pathogen-Specific Immune Fingerprints during Acute Infection: The Diagnostic Potential of Human γδ T-Cells.急性感染期间的病原体特异性免疫指纹：人类γδ T细胞的诊断潜力
Front Immunol. 2014 Nov 13;5:572. doi: 10.3389/fimmu.2014.00572. eCollection 2014.
5
In reply.回复。
Oncologist. 2013;18(8):e26-7. doi: 10.1634/theoncologist.2013-0235.
本文引用的文献
1
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.唑来膦酸辅助治疗乳腺癌患者的系统评价和荟萃分析。
Oncologist. 2013;18(4):353-61. doi: 10.1634/theoncologist.2012-0261. Epub 2013 Feb 12.
2
What lessons can be learned from γδ T cell-based cancer immunotherapy trials?从基于 γδ T 细胞的癌症免疫疗法试验中可以吸取哪些经验教训？
Cell Mol Immunol. 2013 Jan;10(1):35-41. doi: 10.1038/cmi.2012.39. Epub 2012 Dec 17.
3
Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial.单核细胞和 γδ T 细胞控制静脉注射唑来膦酸的急性期反应：来自 IV 期安全性试验的见解。
J Bone Miner Res. 2013 Mar;28(3):464-71. doi: 10.1002/jbmr.1797.
4
Adjuvant bisphosphonates: a new standard of care?辅助双膦酸盐：新的治疗标准？
Curr Opin Oncol. 2012 Nov;24(6):635-42. doi: 10.1097/CCO.0b013e32835771aa.
5
Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis.唑来膦酸作为乳腺癌辅助治疗的疗效：一项系统评价和荟萃分析。
PLoS One. 2012;7(7):e40783. doi: 10.1371/journal.pone.0040783. Epub 2012 Jul 26.
6
The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.唑来膦酸在乳腺癌辅助治疗中的疗效：一项随机对照试验的荟萃分析。
Eur J Cancer. 2012 Jan;48(2):187-95. doi: 10.1016/j.ejca.2011.10.021. Epub 2011 Nov 17.
7
Adjuvant zoledronic acid for breast cancer: mechanism of action?乳腺癌辅助治疗用唑来膦酸：作用机制？
Lancet Oncol. 2011 Oct;12(11):991-2. doi: 10.1016/S1470-2045(11)70252-2.
8
In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.唑来膦酸和低剂量白细胞介素-2体内调节 Vgamma9Vdelta2 T 细胞用于晚期乳腺癌患者的免疫治疗。
Clin Exp Immunol. 2010 Aug;161(2):290-7. doi: 10.1111/j.1365-2249.2010.04167.x. Epub 2010 May 10.
9
In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients.唑来膦酸对早期乳腺癌患者外周γδ T淋巴细胞的体内作用。
Cancer Immunol Immunother. 2009 Jan;58(1):31-8. doi: 10.1007/s00262-008-0521-6. Epub 2008 May 6.
Zotero 插件